Recommended

Amgen secures Uplizna EU approval in gMG
Orsellinic acid study demonstrates production first
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
J&J to site new $1bn cell therapy facility in Pennsylvania
FDA sets new default standard for US drug approvals
Daiichi Sankyo picks new Global Head of R&D
Dr Belén Garijo replaces Paul Hudson as Sanofi CEO
Discover how to harness digital PCR for rapid sterility testing
news

Combination therapy may hold potential for severe viral hepatitis

1
SHARES

New findings from a Phase II study suggest the curative potential of a combination treatment for chronic hepatitis delta virus, according to Gilead Sciences.

Gilead hepatitis

Final Phase IIb data has confirmed the potential of bulevirtide 10mg in combination with pegylated interferon alfa-2a (PegIFN) as a finite therapy for adults with chronic hepatitis delta virus (HDV), according to Gilead Sciences.

 

SPACES ARE FILLING FAST – SECURE YOURS!


Rapid sterility testing is no longer optional for advanced therapies – it’s becoming operationally essential. Join this webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing

18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

The session will discuss future trends in sterility testing and showcase successful rapid sterility testing in cell and gene therapy products, demonstrating practical applications and benefits.

Register now to join live or for free access to the on-demand recording if you can’t make the date

The new data is from the MYR204 study which investigated the efficacy and safety of the first-in-class entry inhibitor bulevirtide alone and together with PegIFN, in these patients with compensated chronic HDV infection.

At present, bulevirtide 2mg is the only approved treatment for adults with chronic hepatitis delta virus and compensated liver disease in the European Economic Area (EEA), Great Britain and Switzerland, Gilead confirmed.

Promise of a finite treatment option for chronic hepatitis delta virus 

New end of study data show that bulevirtide 10mg in combination with PegIFN maintained a 46 percent rate of undetectable HDV RNA at Week 48 after the end of treatment. These findings were presented at the European Association for the Study of the Liver (EASL) Congress 2024.

According to Gilead, data published in NEJM revealed:

  • at Week 24, a total of 32 percent and 46 percent of patients achieved undetectable HDV RNA following treatment with bulevirtide 2mg in combination with PegIFN and bulevirtide 10mg in combination with PegIFN, respectively
  • PegIFN monotherapy and bulevirtide 10mg monotherapy enabled 17 percent and 12 percent to attain undetectable HDV RNA, respectively.

At Week 48 after end of treatment, data presented at EASL (GS-00) demonstrated:

  • undetectable HDV RNA in 26 percent and 46 percent of patients taking bulevirtide 2mg combined with PegIFN and bulevirtide 10mg in combination with PegIFN, respectively
  • PegIFN monotherapy and bulevirtide 10mg monotherapy enabled undetectable HDV RNA to be achieved by 25 percent and 12 percent of patients, respectively.

These new data support the potential for bulevirtide as a finite treatment option, demonstrating that almost half of people treated with bulevirtide 10mg in combination with PegIFN remained undetectable for HDV RNA one year after treatment cessation”

“Hepatitis delta virus is the most severe form of viral hepatitis….These new data support the potential for bulevirtide as a finite treatment option, demonstrating that almost half of people treated with bulevirtide 10mg in combination with PegIFN remained undetectable for HDV RNA one year after treatment cessation,” shared Dr Tarik Asselah, PhD, Professor of Hepatology, Hôpital Beaujon APHP, Université Paris-Cité, Head of Viral Hepatitis, UMR1149 Inserm and principal investigator of the study.

“These long-term data are the highest post-treatment response rates ever reported for HDV,” Dr Asselah added.

“In addition to highlighting the curative potential of combination therapy for some people with chronic hepatitis delta virus, these final data support the safety profile of bulevirtide,” noted Anu Osinusi, Vice President, Clinical Research for Hepatitis, Respiratory and Emerging Viruses, Gilead Sciences.

 
Share via
Share via